Apnea-Tech is a digital health start-up company based in the Northwest of England. We have developed a purposeful, low-cost sleep apnoea screening device, MHRA registered and UKCA accredited.
There are 1 Billion people worldwide with Sleep Apnoea
Only 20% are diagnosed
The problem space
About 90% of people with sleep apnoea have Obstructive Sleep Apnoea (OSA), which is a chronic condition characterised by frequent upper airway collapse during sleep, leading to co-morbidities such as systemic hypertension, cardiovascular disease, stroke, and abnormal glucose metabolism, all of which impose a significant health economic burden.
Research indicates that 935 million globally have mild-to-severe OSA, with 425 million with moderate-to-severe OSA. Over 80% of those affected remain undiagnosed and therefore untreated. The numbers affected are rising due to increasing obesity.
An accessible screening device is crucial to properly identify those people with OSA who should be treated.
Simple innovative design with two patents granted and one pending
Lightweight, sustainable device
Records events in the breath pathway
The solution
ApneScan-DC1
ApneScan DC-2 AI (in development)
The ApneScan-DC1 is a purposeful, low-cost sleep apnoea screening device, MHRA registered and UKCA accredited.
- Simple, Lightweight wearable device
- Records actual events in the breath pathway
- Data is analysed using Model-Driven Engineering techniques to identify events
- The device is low cost, disposable and environmentally friendly
- UKCA Class I certified and MHRA registered
- Full diagnostic in development in collaboration with IBM, STFC, Keele University and University Hospitals of North Midlands
Sleep Apnoea stratification made simple
Andy Moss
Founder & Chief Executive Officer
Andy is an accomplished executive with over 30 years of experience in the Healthcare and MedTech industries. He has board-level expertise from working with multinationals and SMEs in Medical Devices and Pharmaceuticals. Andy has held various C-suite and senior roles across the EU, specialising in Marketing, Market Access, Development, and Pricing & Reimbursement. At Boston Scientific, he built and led the EMEA Pulmonary team, successfully launching innovative devices like Bronchial Thermoplasty for severe asthma.
Jeremy Walsh
Founder & Chief Technical Officer
Jeremy is a serial entrepreneur with over 20 years in the MedTech industry. He co-founded Apnea-Tech with Andy Moss in 2020. Prior to this, he led Cambridge Respiratory Innovations Limited (now TidalSense Limited), developing the innovative N-Tidal respiratory device, securing nearly £5 million in funding, and achieving Class I CE-marking. Previously, Jeremy co-founded Anaxsys, also in respiratory diagnostics. His career includes significant roles in healthcare information services, contributing to two NASDAQ IPOs. Jeremy holds a degree in Aeronautical Engineering and began his career as a jet pilot in the Royal Air Force.
Development supported by:
Awarded two Smart grants to Apnea-Tech to test the feasibility of the team’s concept and then develop a first-generation device. This has resulted in the ApneScan DC1 and the SABRES clinical study at University Hospitals of North Midlands.
Keele University Business Bridge has supported Apnea-Tech in the development of the first generation apnoea and hypopnea identification algorithm.
Apnea-Tech has been supported by NIHR i4i FAST funding to explore with clinicians the importance of novel sleep apnoea metrics which can be delivered by its ApneScan device.
Centre for Process Innovation has supported Apnea-Tech in the development of its internal systems towards ISO 13485 standards.
Science Technologies Research Council funding is supporting the development of an SPO2 proxy from the ApneScan breath pathway signal. The development work is being completed by an AI team at IBM UK.
Diagnostics Development Hub (DxD Hub) is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). Apnea-Tech are delighted to have them on board alongside the MedTech Catapult team in Singapore as a part of our product development programme.
Our ApneScan sleep apnoea diagnostic has been selected by MedTech Catapult, Singapore’s first dedicated MedTech productisation initiative as part of their programme. Supported by a £1.3m non dilutive development grant.
Enquiries
Apnea-Tech’s founders are actively seeking strategic partners to further refine and commercialise their affordable sleep apnoea screening and diagnostic solutions.